ClinicalTrials.gg
TerminatedNCT00513305Updated Aug 1, 2012Results posted

Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia

A Phase 3 interventional study of Arsenic trioxide and Low-dose cytarabine alone in Acute Myeloid Leukemia, sponsored by Cephalon. Terminated at 12 sites in 2 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2012-08-01.

Sponsored by Cephalon (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Study has been stopped by sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing Arsenic Trioxide in Leukemia, Myeloid, Acute — 2 open to participants now, 2 under way, none of them phase 3. Arsenic Trioxide · Leukemia, Myeloid, Acute.

Enrollment
2nd of 13
67 · median 13
Started
2007
with 1 other
Phase 3
Only one
of the 14
Registered
8th of 14
by date
Lead sponsor
1 of 14
Cephalon

Among the 14 studies testing Arsenic Trioxide in Leukemia, Myeloid, Acute, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2007, is the only one in phase 3, and was the 8th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

2 of the 14 studies testing Arsenic Trioxide in Leukemia, Myeloid, Acute are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Arsenic Trioxide

Arsenic Trioxide: first FDA approval 2000 (TRISENOX), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Arsenic Trioxide in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The primary objective of this study is to determine whether low-dose cytarabine in combination with arsenic trioxide is more effective than low-dose cytarabine alone in achieving complete remission in elderly patients (≥60 years of age) with acute myeloid leukemia.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • acute myeloid leukemia, cytarabine, arsenic trioxide.
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has confirmed acute myeloid leukemia (AML).
  • The patient is unwilling or unable to tolerate conventional induction chemotherapy.
  • The patient has no comorbid conditions that would limit to less than 3 months.
  • Patient must meet specific laboratory parameters for study inclusion.

Exclusion criteria

Exclusion Criteria:

  • The patient has had previous cytotoxic chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Previous treatment with low-dose cytarabine is not permitted.

  • The patient has a outside of the protocol-specified range.
  • The patient has laboratory values outside of protocol-specified ranges.
  • The patient is concurrently treated with cytotoxic therapy, radiation, or agents.
  • The patient has uncontrolled, severe cardiovascular or pulmonary disease or other uncontrolled medical condition.
  • The patient has known central nervous system involvement with AML.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Active comparator
    Low-dose cytarabine plus arsenic trioxide

    Cycle 1 cytarabine 10 mg/m\^2 was administered subcutaneously (sc) twice daily (bid) on days 1-14. 0.25 mg/kg arsenic trioxide was administered intravenously (iv) on days 1-5 and days 8-12. Cycle 2 A second identical cycle of cytarabine and arsenic trioxide was given to patients with persistent disease. Patients who achieved complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine and arsenic trioxide with the doses and schedule identical to the initial cycle. A recovery period of up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of arsenic trioxide 0.25 mg/kg iv on days 1 and 4 and cytarabine 10 mg/m\^2 sc bid on days 1 through 7 of a 28-day cycle.

    Drug: Arsenic trioxide · Drug: Low-dose cytarabine alone

  • Active comparator
    Low-dose cytarabine alone

    Cytarabine was administered at a dose of 10 mg/m\^2 sc bid from days 1-14 of cycle 1. A second identical cycle of cytarabine was given to patients with persistent disease. Patients who achieved a complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine with the doses and schedule identical to the initial treatment cycle. Recovery period up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of cytarabine at 10 mg/m\^2 sc bid on days 1-7 of a 28-day cycle. Patients started maintenance treatment within 42 days after platelet count recovery. Maintenance treatment continued for 2 years or until unacceptable toxicity or disease progression.

    Drug: Low-dose cytarabine alone

Interventions

  • Arsenic trioxide will be administered intravenously (iv) at a dose of 0.25 mg/kg.

  • Cytarabine will be administered at a dose of 10 mg/m\^2 subcutaneously (sc) twice a day (bid).

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Complete Remission (CR)

    The primary efficacy variable was the percentage of subjects in each treatment group who achieved complete remission after treatment with study drug. Complete remission was defined as: 1) Less than 5% blasts in normocellular bone marrow sample. 2) No blasts in bone marrow sample containing Auer rods. 3)Clearance of previous extramedullary disease. 4)Normal values for absolute neutrophil count (at least 1000/microliter), platelet count (at least 100,000/microliter), without platelet transfusions, and in absence of peripheral myeloblasts.

    Time frame: From baseline through Day 70. Assessments were performed on Day 21 in cycle 1, no later than Day 56 of cycle 1 or 2 (if applicable), and no later than Day 70 of cycle 1 or 2 (if applicable) or at any other time at the discretion of the investigator

Secondary outcomes

  1. Number of Participants Who Died or Were Censored by 24 Months

    This measure (time to death or censor) was defined for all enrolled subjects from the date of randomization until death from any cause. If a subject was not known to have died by the end of the followup period, observation of overall survival was censored on the date the patient was last known to be alive. The number of participants who died or were censored is presented here. (Note: all subjects participating in this study had either died or were censored by 24 months.)

    Time frame: From Baseline through 24 months following Baseline

  2. Proportion of Participants With Relapse-Free Survival (RFS)Using the Kaplan-Meier Estimate

    RFS is defined for patients who achieved a complete remission (CR), complete remission with incomplete platelet recovery (CRp), or partial remission(PR), and was measured from the date of attaining CR, CRp, or PR until the date of AML relapse or death from any cause, whichever occurred first. For a patient not known to have relapsed or died by the end of the study followup, observation of relapse free survival was censored on the date of the last followup examination. The Kaplan Meier Estimate of relapse-free survival at Month 3 and Month 6 is presented here.

    Time frame: From Baseline (randomization) through 24 months following Baseline

  3. Number of Participants Who Experienced Early Death

    Early death is defined as death from any cause within the first 14 days after start of study drug treatment. The number of patients in each study group who experienced early death is presented here.

    Time frame: 14 days from start of study drug treatment

  4. Number of Participants Who Experienced Induction (Thirty-Day) Mortality

    The number of subjects who died from any cause within the first 30 days after the start of study drug treatment is presented here.

    Time frame: Up to 30 days following start of study drug treatment

  5. Proportion of Participants Surviving at 6 Months and 12 Months Using the Kaplan Meier Estimate

    The duration of overall survival was defined for all patients and was measured from the date of randomization until death from any cause. For a patient who was not known to have died by the end of the follow-up period, observation of overall survival was censored on the date the patient was last known to be alive. The estimate of likelihood of survival at 6 and 12 months after Baseline using the Kaplan Meier Estimate is presented here.

    Time frame: Baseline through 12 months

07

Results

Posted Mar 29, 2011
Limitations and caveats
In September 2009, the sponsor decided to stop the study due to difficulty in enrollment. The study was stopped prior to the first planned interim analysis. Most of the analysis planned in the protocol was not performed.

Participant flow

Seven centers in the United States and one center in Canada. First patient enrolled 12 October 2007; last patient completed protocol-specified treatment 5 July 2009; last patient completed survival follow-up contact 16 December 2009.

Participant flow — Overall Study
MilestoneLow-dose Cytarabine Plus Arsenic TrioxideLow-dose Cytarabine Alone
Started3334
Completed57
Not completed2827
Withdrew: Adverse event62
Withdrew: Death (through consolidation treatment)22
Withdrew: Lack of efficacy813
Withdrew: Withdrawal by subject12
Withdrew: Disease progression85
Withdrew: Eligible for stem cell transplant10
Withdrew: Hematologic counts did not recover10
Withdrew: Physician decision10
Withdrew: Persistent hypocellularity01
Withdrew: Sponsor decision02

Outcome measures

PrimaryPercentage of Participants in Complete Remission (CR)

The primary efficacy variable was the percentage of subjects in each treatment group who achieved complete remission after treatment with study drug. Complete remission was defined as: 1) Less than 5% blasts in normocellular bone marrow sample. 2) No blasts in bone marrow sample containing Auer rods. 3)Clearance of previous extramedullary disease. 4)Normal values for absolute neutrophil count (at least 1000/microliter), platelet count (at least 100,000/microliter), without platelet transfusions, and in absence of peripheral myeloblasts.

Time frame:
From baseline through Day 70. Assessments were performed on Day 21 in cycle 1, no later than Day 56 of cycle 1 or 2 (if applicable), and no later than Day 70 of cycle 1 or 2 (if applicable) or at any other time at the discretion of the investigator
Reported as:
Number · Percentage of participants in CR
Percentage of Participants in Complete Remission (CR)
Percentage of participants in CRLow-dose Cytarabine Plus Arsenic TrioxideLow-dose Cytarabine Alone
Percentage of Participants in Complete Remission (CR)15.2 (0.051 to 0.319)8.8 (0.019 to 0.0237)
Statistical analysis
  • Low-dose Cytarabine Plus Arsenic Trioxide vs Low-dose Cytarabine Alone · Chi-squared · p = 0.425 (The p-value is from the Pearson chi-square test for testing the equality of two binomial proportions, assuming normal approximation of the binomial proportions.)There were no adjustments for covariates. Since the primary endpoint was prespecified, no adjustment for multiplicity of endpoints was introduced
SecondaryNumber of Participants Who Died or Were Censored by 24 Months

This measure (time to death or censor) was defined for all enrolled subjects from the date of randomization until death from any cause. If a subject was not known to have died by the end of the followup period, observation of overall survival was censored on the date the patient was last known to be alive. The number of participants who died or were censored is presented here. (Note: all subjects participating in this study had either died or were censored by 24 months.)

Time frame:
From Baseline through 24 months following Baseline
Reported as:
Number · Participants
Number of Participants Who Died or Were Censored by 24 Months
ParticipantsLow-dose Cytarabine Plus Arsenic TrioxideLow-dose Cytarabine Alone
Number of Participants Who Died or Were Censored by 24 Months3334
Statistical analysis
  • Low-dose Cytarabine Plus Arsenic Trioxide vs Low-dose Cytarabine Alone · Log Rank · p = 0.829 · Cox proportional hazard: 1.027 · 95% CI 0.535 to 1.973
SecondaryProportion of Participants With Relapse-Free Survival (RFS)Using the Kaplan-Meier Estimate

RFS is defined for patients who achieved a complete remission (CR), complete remission with incomplete platelet recovery (CRp), or partial remission(PR), and was measured from the date of attaining CR, CRp, or PR until the date of AML relapse or death from any cause, whichever occurred first. For a patient not known to have relapsed or died by the end of the study followup, observation of relapse free survival was censored on the date of the last followup examination. The Kaplan Meier Estimate of relapse-free survival at Month 3 and Month 6 is presented here.

Time frame:
From Baseline (randomization) through 24 months following Baseline
Reported as:
Number · Proportion of participants
Proportion of Participants With Relapse-Free Survival (RFS)Using the Kaplan-Meier Estimate
Proportion of participantsLow-dose Cytarabine Plus Arsenic TrioxideLow-dose Cytarabine Alone
Month 3 (95% Confidence Interval)0.818 (0.447 to 0.951)0.800 (0.204 to 0.969)
Month 6 (95% Confidence Interval)0.818 (0.447 to 0.951)0.800 (0.204 to 0.969)
Statistical analysis
  • Low-dose Cytarabine Plus Arsenic Trioxide vs Low-dose Cytarabine Alone · Log Rank · p = 0.527 · Cox proportional hazard: 2.310 · 95% CI 0.160 to 33.343Estimate based on Cox Proportional Hazards Model adjusting for age, Eastern Cooperative Oncology Group (ECOG) status, white blood count and presence of antecedent hematologic disorder.
SecondaryNumber of Participants Who Experienced Early Death

Early death is defined as death from any cause within the first 14 days after start of study drug treatment. The number of patients in each study group who experienced early death is presented here.

Time frame:
14 days from start of study drug treatment
Reported as:
Number · Participants
Number of Participants Who Experienced Early Death
ParticipantsLow-dose Cytarabine Plus Arsenic TrioxideLow-dose Cytarabine Alone
Number of Participants Who Experienced Early Death02
SecondaryNumber of Participants Who Experienced Induction (Thirty-Day) Mortality

The number of subjects who died from any cause within the first 30 days after the start of study drug treatment is presented here.

Time frame:
Up to 30 days following start of study drug treatment
Reported as:
Number · Participants
Number of Participants Who Experienced Induction (Thirty-Day) Mortality
ParticipantsLow-dose Cytarabine Plus Arsenic TrioxideLow-dose Cytarabine Alone
Number of Participants Who Experienced Induction (Thirty-Day) Mortality32
SecondaryProportion of Participants Surviving at 6 Months and 12 Months Using the Kaplan Meier Estimate

The duration of overall survival was defined for all patients and was measured from the date of randomization until death from any cause. For a patient who was not known to have died by the end of the follow-up period, observation of overall survival was censored on the date the patient was last known to be alive. The estimate of likelihood of survival at 6 and 12 months after Baseline using the Kaplan Meier Estimate is presented here.

Time frame:
Baseline through 12 months
Reported as:
Number · Proportion of Participants
Proportion of Participants Surviving at 6 Months and 12 Months Using the Kaplan Meier Estimate
Proportion of ParticipantsLow-dose Cytarabine Plus Arsenic TrioxideLow-dose Cytarabine Alone
Month 6 (95% Confidence Interval)0.626 (0.435 to 0.768)0.649 (0.454 to 0.789)
Month 12 (95% Confidence Interval)12.22 (4.37 to 16.76)8.51 (5.72 to 19.65)
Statistical analysis
  • Low-dose Cytarabine Plus Arsenic Trioxide vs Low-dose Cytarabine Alone · Log Rank · p = 0.8289 · Cox proportional hazard: 1.027 · 95% CI 0.535 to 1.973Estimate based on Cox Proportional Hazards Model adjusting for age, Eastern Cooperative Oncology Group (ECOG) status, white blood count and presence of antecedent hematologic disorder.

Adverse events

Collected over approximately 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low-dose Cytarabine Plus Arsenic Trioxide—19/33 (57.6%)33/33 (100%)
Low-dose Cytarabine Alone—21/33 (63.6%)33/33 (100%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventLow-dose Cytarabine Plus Arsenic TrioxideLow-dose Cytarabine Alone
Febrile neutropeniaBlood and lymphatic system disorders7/339/33
PneumoniaInfections and infestations3/333/33
DehydrationMetabolism and nutrition disorders1/332/33
Lung infiltrationRespiratory, thoracic and mediastinal disorders0/332/33
Neutropenic sepsisInfections and infestations2/331/33
Pneumonia fungalInfections and infestations2/330/33
Renal failureRenal and urinary disorders2/330/33
Renal failure acuteRenal and urinary disorders1/332/33
Respiratory distressRespiratory, thoracic and mediastinal disorders2/331/33
Respiratory failureRespiratory, thoracic and mediastinal disorders2/330/33
Most frequent other events
Showing 10 of 150
Most frequent other events
EventLow-dose Cytarabine Plus Arsenic TrioxideLow-dose Cytarabine Alone
DiarrhoeaGastrointestinal disorders21/3314/33
Febrile neutropeniaBlood and lymphatic system disorders9/3316/33
Oedema peripheralGeneral disorders16/3314/33
NauseaGastrointestinal disorders15/339/33
ConstipationGastrointestinal disorders14/3311/33
HypotensionVascular disorders13/339/33
PyrexiaGeneral disorders9/3312/33
FatigueGeneral disorders10/339/33
HeadacheNervous system disorders10/334/33
TachycardiaCardiac disorders6/3310/33

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Low-dose Cytarabine Plus Arsenic TrioxideLow-dose Cytarabine AloneTotal
<=18 years000
Between 18 and 65 years9716
>=65 years242751
Age Continuous
Age Continuous(years)Low-dose Cytarabine Plus Arsenic TrioxideLow-dose Cytarabine AloneTotal
Mean70.9 ± 7.171.5 ± 6.871.2 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)Low-dose Cytarabine Plus Arsenic TrioxideLow-dose Cytarabine AloneTotal
Female161733
Male171734
Region of Enrollment
Region of Enrollment(participants)Low-dose Cytarabine Plus Arsenic TrioxideLow-dose Cytarabine AloneTotal
United States323264
Canada123
08

Study locations

12 sites
  • USC / Norris Cancer Hospital
    Los Angeles, California 90033, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • University of Illinois
    Chicago, Illinois 60612, United States
  • Indiana Oncology Hematology Consultants
    Indianapolis, Indiana 46202, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • St. Vincent's Comprehensive Cancer Center
    New York, New York 10011, United States
  • Weill Medical College of Cornell University
    New York, New York 10021, United States
  • Brody School of Medicine
    Greenville, North Carolina 27834, United States
  • University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • UT Health Science Center
    San Antonio, Texas 78229, United States
  • Princess Margaret Hospital
    Toronto, Ontario M5G2M9, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Jul 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2007
First posted
Aug 8, 2007
Start
Oct 2007
Primary completionActual
Jul 2009
CompletionActual
Dec 2009
Results first posted
Mar 29, 2011
Last update
Aug 1, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00513305
Lead sponsor
Cephalon
Responsible party
Sponsor
First posted
Aug 8, 2007
Start date
Oct 2007
Primary completion
Jul 2009
Completion
Dec 2009
Results posted
Mar 29, 2011
Last update
Aug 1, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arsenic Trioxide

Start the discussion